The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan

When feasible, conversion therapy should be considered to improve the prognosis of u-HCC patients treated with Atez/Bev. Moreover, oncological resectability criteria may provide a useful tool for investigators regarding conversion therapy.

Authors

Institutions

Publication Details

Journal
Hepatology International
Published
2025-02-28
DOI
https://doi.org/10.1007/s12072-025-10781-y
Citations
3
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
3.97
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan

Hideki Kobara, Tomotake Shirono, Yasuto Takeuchi, Takafumi Yamamoto et al.
3 citations
Hepatology International
Hepatocellular Carcinoma Treatment and Prognosis
3.97
article

The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan

Hideki Kobara, Tomotake Shirono, Yasuto Takeuchi, Takafumi Yamamoto, Norikazu Tanabe, Joji Tani, Yuki Kanayama, Taro Takami, Takeshi Hatanaka, Tetsuji Takayama, Tetsu Tomonari, Shigeo Shimose, Ryu Sasaki, Kyo Sasaki, Motoyuki Otsuka, Atsushi Naganuma, Hiroki Kawashima, Satoru Kakizaki, Issei Saeki, Takanori Ito, Hideki Iwamoto, Takumi Kawaguchi, Sohji Nishina
article en
3 citations

Abstract

When feasible, conversion therapy should be considered to improve the prognosis of u-HCC patients treated with Atez/Bev. Moreover, oncological resectability criteria may provide a useful tool for investigators regarding conversion therapy.

Hepatology InternationalVol. 19(4)
Kurume University (JP), Yamaguchi University (JP), Kawasaki Medical School (JP), Kagawa University (JP), Okayama University Hospital (JP), National Hospital Organization Takasaki Medical Center (JP), Gunma Saiseikai Maebashi Hospital (JP), Nagasaki University (JP), Nagoya University (JP), Tokushima University (JP)
Openalex Percentile: Top 7%
Hepatocellular Carcinoma Treatment and Prognosis
3.97
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.